Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS).[8] It is intended for once-daily oral administration.[10][8]
In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1]
^ ab"FDA approves new oral drug to treat multiple sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 26 March 2019. Archived from the original on 27 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
^"Mayzent Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Retrieved 23 August 2020.
^"Summary for ARTG Entry:310499 Mayzent siponimod 2 mg film-coated tablet blister pack" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.[permanent dead link]
^"Australian Public Assessment Report for Siponimod" (PDF). Therapeutic Goods Administration (TGA).
^"Mayzent Product information". Health Canada. Retrieved 29 May 2022.
^"Summary Basis of Decision (SBD) for Mayzent". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^"Mayzent 2 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 24 April 2020. Retrieved 23 August 2020.
^ abc"Mayzent- siponimod tablet, film coated". DailyMed. 26 March 2019. Retrieved 22 January 2020.
^Cite error: The named reference Mayzent EPAR was invoked but never defined (see the help page).
^Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. (2014). "Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial". Multiple Sclerosis and Related Disorders. 3 (6): 752. doi:10.1016/j.msard.2014.09.185. ISSN 2211-0348.
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis...
or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of...
for S1P1 over other S1 receptors, relative to related S1 active agents siponimod and the phosphorylated (prodrug) forms of fingolimod and mocravimod, where...
Retrieved 16 October 2019. "Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease"...
therapies to the clinic, including erenumab (Aimovig) for migraine and siponimod (Mayzent) for multiple sclerosis. After seven years at NIBR, Dolmetsch...
In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis. Siponimod was approved...
treatment and the first oral therapy approved for multiple sclerosis. Siponimod (Mayzent), oral. Approved in March 2019 for CIS, RRMS and SPMS Ozanimod:...
Global Information
This article incorporates text from this source, which is in the public domain.
